June 3, 2020 / 8:44 AM / a month ago

BRIEF-Genmab -U.S.FDA Extends Review

June 3 (Reuters) - Genmab A/S:

* REG-U.S. FDA EXTENDS REVIEW OF SBLA, SUBMITTED BY NOVARTIS, FOR OFATUMUMAB IN RELAPSING MULTIPLE SCLEROSIS

* REGULATORY ACTION IN THE U.S. NOW ANTICIPATED IN SEPTEMBER 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below